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Abstract: Sedation plays a central role in making colonoscopy tolerable for patients and feasible 
for the endoscopist to perform. The array of agents used for endoscopic sedation continues to 
evolve. Fospropofol (FP), a prodrug of propofol with a slower pharmacokinetic proﬁ  le, is currently 
under evaluation for use during endoscopic procedures. Preliminary data suggests that FP dosed at 
6.5 mg/kg is well tolerated by most patients with perineal paresthesias being the most commonly 
experienced adverse effect. This article will examine the current literature on the use of FP for the 
sedation of patients undergoing colonoscopy, highlighting the pharmacokinetics, pharmacodynam-
ics, risks, and common adverse events associated with the novel sedative/hypnotic.
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Introduction
Sedation during colonoscopy is important for making the procedure comfortable for 
patients and feasible for the gastroenterologist. The use of procedural sedation enables 
the endoscopist to perform a thorough exam while minimizing patient anxiety and risk 
of injury. All major US gastroenterology societies support the administration of seda-
tion by properly trained gastroenterologists performing routine endoscopic procedures 
on average risk patients. Since its introduction in the 1980s, propofol (Diprivan®, 
2,6-diisopropylphenol; AstraZeneca Pharmaceuticals) has been used for an increasing 
number of procedures due to its rapid onset and short elimination half-life. Propofol has 
several advantages over benzodiazepines and opiates including a faster onset of action, 
high patient satisfaction, and a more rapid recovery to full levels of consciousness with 
minimal residual sedative effects (Sipe et al 2002). When used as an infusion, propofol 
produces a rapid peak plasma concentration that may quickly induce deep sedation. Due 
to this rapid pharmacokinetic proﬁ  le, concerns have been expressed regarding propofol’s 
potential to induce deeper levels of sedation than intended when patients are improperly 
monitored. For this reason the product label endorsed by the US Food and Drug Admin-
istration (FDA) has limited the use of propofol to anesthesia specialists (AstraZeneca 
Pharmaceuticals 2004). In this environment, attention has been drawn to formulations 
of propofol that may be more acceptable for non-anesthesiologist administration.
Fospropofol disodium (Aquavan® injection; MGI Pharma, Inc, Bloomington, MN, 
USA) is a water-soluble prodrug of propofol currently under investigation for diagnostic 
procedures. Fospropofol (FP) is rapidly hydrolyzed by endothelial alkaline phosphatases 
in vivo after intravenous administration, releasing propofol, phosphate, and formalde-
hyde (Figure 1). FP-derived propofol is the active compound that provides sedation 
and has a slower pharmacokinetic and pharmacodynamic proﬁ  le than propofol lipid 
emulsion. Other metabolites of FP do not accumulate above endogenous levels (Fechner 
et al 2003). This article will review the current understanding of FP’s pharmacokinetics, 
pharmacodynamics, risks, and beneﬁ  ts for sedation during colonoscopy. It will also 
examine the recent clinical trials utilizing FP for endoscopic sedation.Therapeutics and Clinical Risk Management 2008:4(4) 734
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Potential advantages of fospropofol
One potential advantage of FP is that the manufacturer is 
seeking approval from the FDA for FP administration by non-
anesthesia specialists (Rex 2006). This may permit a wider 
spectrum of properly trained physicians to use FP than propofol 
emulsion. Another potential advantage of FP over propofol 
relates to its nonlipid formulation. Propofol emulsion, as a lipid-
based formula, is prone to contamination and is a poor choice 
for patients with hyperlipidemia. These risks are ameliorated 
by FP which does not utilize a lipid suspension for compound 
delivery. The pharmacokinetic proﬁ  le of FP has both advan-
tages and disadvantages. The advantage is that its slower proﬁ  le 
allows for an ease of administration that requires less frequent 
bolusing of medication for brief endoscopic procedures (Rex 
2006). While this potential advantage may have relevance in a 
busy, clinical setting, it must be put into the context of a slower 
onset of action and a prolonged recovery time.
Risks of fospropofol
The most frequently observed adverse events from FP 
administration are self-limited, mild to moderate discomfort 
on infusion, perineal paresthesias, and pruritus (Rex et al 
2007a, b; Cohen 2008). In one open label, phase II clinical 
trial in patients undergoing colonoscopy, transient mild 
to moderate perineal tingling, itching, or burning were 
experienced in 85% of patients (Pruitt et al 2005). While 
the mechanism behind this reaction remains unknown, other 
intravenous medications that contain phosphate esters such 
as fosphenytoin and dexamethasone have been noted to cause 
similar side effects (Luer 1998; Perron et al 2003). FP may 
cause small increases in the levels of serum phosphorus, 
although no clinically significant adverse events from 
hyperphosphatemia have been reported (Fechner et al 2004; 
Gibiansky et al 2005).
Although FP is associated with a hemodynamic proﬁ  le 
comparable to that of propofol, one study noted that FP 
produced an early tachycardia in healthy volunteers (Struys 
et al 2005). A note of caution is necessary as deeper than 
intended sedation with fospropofol (due to a longer half-
life) should be expected to last longer than deep sedation 
inadvertently induced with propofol. As with all agents used 
for sedation, excessive dose escalation can lead to deeper 
than intended degrees of sedation and concomitant apnea or 
airway compromise. Respiratory depression remains a clinical 
precursor to more serious compromise in cardiovascular 
function, and adequate monitoring of patients undergoing 
sedation remains essential (Rex et al 2005).
Drug combinations
Propofol emulsion and FP can both be titrated to moderate 
sedation when co-administered with narcotics, benzodiaz-
epines, or both (Cohen et al 2004; Rex 2006; VanNatta and 
Rex 2006). As FP is a pure sedative/hypnotic without analgesic 
properties, it has recently been studied with co-administration 
of an opiate to improve pain control and to allow for success-
ful targeting of moderate sedation (Rex 2006). Fentanyl 50 μg 
prior to initial bolus dosing of FP is the analgesic dose favored 
in recent clinical trials (Rex et al 2007a, b; Cohen 2008).
Pharmacokinetics of fospropofol
After intravenous administration of FP, propofol is released 
from its prodrug by the enzymatic activity of alkaline 
phosphatases in the vascular endothelium (Figure 1) (Fechner 
et al 2003). This mechanism of action provides a controlled 
liberation of propofol with a smooth increase in plasma pro-
pofol concentration. Despite generating the same functional 
compound as propofol emulsion, FP-derived propofol has 
a different pharmacodynamic and pharmacokinetic proﬁ  le 
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(Figure 2) (Shah et al 2007). Notably, FP has an extended 
elimination half-life, a longer residence time, and a delayed 
onset of action (Schywalsky et al 2003; Fechner et al 2004).
Propofol is eliminated in three phases. The ﬁ  rst phase of 
elimination (t½α) occurs within 2–3 minutes after intravenous 
administration and represents the delivery of propofol through-
out body tissues. The second phase of elimination (t½β) is a 
longer period lasting 30–60 minutes and represents the metabo-
lism of propofol. The ﬁ  nal stage of elimination (t½γ) is a much 
longer stage of variable duration. This stage can last 2–45 hours 
and represents ongoing metabolism of drug as it slowly emerges 
from poorly perfused adipose tissue (Gan 2006).
Pharmacodynamics
Preliminary studies suggested that at equal plasma propo-
fol concentrations, FP-derived propofol yielded a stronger 
pharmacodynamic effect than that seen with propofol emulsion 
without a signiﬁ  cant hysteresis (Fechner et al 2004). However, a 
later study found that the pharmacodynamic effect of propofol-
emulsion and FP-derived propofol were similar once adjusted 
for intracerebral propofol concentration (Levitt and Schnider 
2005). Continuous intravenous infusion of FP produces dose-
dependent sedation as measured by the Modiﬁ  ed Observer’s 
Assessment of Alertness/Sedation (MOAA/S) score and the 
bispectral index (BIS) (Fechner et al 2005). Fechner and col-
leagues demonstrated that FP-delivered propofol at a plasma 
concentration of 1.8 μg/mL or a bolus of 10 mg/kg were most 
likely to achieve a MOAA/S score of 3, equivalent to the mod-
erate degree of sedation targeted for endoscopic procedures 
(Fechner et al 2005). Other researchers have demonstrated a 
curvilinear relationship between escalating doses of FP and 
pharmacodynamic effect, with doses up to 20 mg/kg producing 
a linear response (Gibiansky et al 2005).
Trials using fospropofol sedation 
during endoscopic procedures
To date there are no large scale trials comparing outcomes 
of FP with those of propofol. However, multiple clinical 
trials have compared the use of FP with benzodiazepines 
and opiates for endoscopic sedation. One randomized, 
double-blind, multicenter trial examined rates of sedation 
success in 127 adult subjects undergoing colonoscopy 
using FP (2, 5, 6.5, or 8 mg/kg) with American Society 
of Anesthesiologist (ASA) risk classes of 1 through 4 
(Cohen et al 2006; Cohen 2008). Sedation success was 
deﬁ  ned as completion of the colonoscopy without a need 
for mechanical/manual ventilation and without the need for 
alternative sedative medication. Sedation success rates were 
dose dependent, with 24.0% in the 2 mg/kg arm, 34.6% in 
the 5 mg/kg arm, 69.2% in the 6.5 mg/kg arm, and 95.8% 
in the 8 mg/kg arm achieving this endpoint (p  0.001). 
No patient required assisted ventilation and no deaths were 
reported. The authors concluded that a 6.5 mg/kg dose of 
FP produced the optimal balance of efﬁ  cacy and safety for 
patients undergoing colonoscopy (Cohen et al 2006; Cohen 
2008). While sedation success was high in the FP 8 mg/kg 
arm, 25% of these patients experienced deep sedation 
during colonoscopy. In contrast, a low 3.8% incidence 
of deep sedation was experienced by subjects in both the 
5 and 6.5 mg/kg groups. This highlights the curvilinear dose-
response curve seen with FP. At doses beyond 6.5 mg/kg, 
small dose escalations produce an exponentially greater risk 
of deep sedation, thereby making the 8 mg/kg dose a poor 
choice for targeting moderate sedation.
Some data on fospropofol are currently available only in 
abstract and poster form after formal presentation at Diges-
tive Disease Week 2007. Preliminary data from a larger 
double-blind, multi-center trial of 314 patients undergoing 
colonoscopy age 18 years with ASA risk classes of 1 to 
4 demonstrated similar results (Cohen et al 2007a, b; Rex 
et al 2007b). Patients received either FP 2.0 mg/kg, FP 
6.5 mg/kg, or midazolam 0.02 mg/kg after pretreatment 
with 50 μg of fentanyl citrate. Midazolam was integrated 
into this study purely as a reference for safety analyses and 
the study was not powered to show differences between FP 
and midazolam. Sedation success was deﬁ  ned as a MOAA/S 
score of 4 after administration of sedation and completion 
of the colonoscopy without use of any alternative sedatives 
Figure 2 Mean (±1 SD) plasma propofol concentration after 10 mg/kg bolus dose of 
fospropofol vs 50 mg/min infusion of propofol x 3–4 minutes in 12 healthy subjects. 
Reprinted with permission from Shah A, Fechner J, Struys M, et al 2007. Differential 
PK/PD of propofol after intravenous fospropofol and diprivan in healthy subjects. 
Anesthesiology, 107:A46. 
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or mechanical/manual ventilation. Sedation success was 
attained in 87%, 26%, and 69% for FP 6.5 mg/kg, FP 2.0 
mg/kg, and 0.02 mg/kg midazolam group, respectively 
(Rex et al 2007d). No FP-related serious adverse events or 
deaths were reported and no patient required either manual 
or mechanical ventilation. The investigators concluded 
that the dose of 6.5 mg/kg is a safe and effective regimen 
in providing minimal to moderate sedation for patients 
undergoing colonoscopy.
To measure patient satisfaction, the investigators had 
patients complete a 6-question satisfaction survey follow-
ing discharge to gauge satisfaction and comfort on a 10 
point scale, 1 indicating low satisfaction or comfort, and 
10 indicating high satisfaction or comfort (Cohen et al 
2007b, d). Mean satisfaction scores were 9.4 in the FP 6.5 
mg/kg group and 9.1 in the FP 2 mg/kg group (Cohen et al 
2007d). Mean comfort scores were 9.1 in the FP 6.5 mg/kg 
group and 8.7 in the FP 2 mg/kg group. Physicians also 
ranked their satisfaction on a similar 10 point scale. Of note, 
physicians in this study were responsible for the dosing of 
sedation and remained unblinded to the medications being 
administered. Physician assessments were taken both at the 
end of the sedation initiation phase and after completion of 
the colonoscopy. Mean physician satisfaction scores with 
the FP 2.0 mg/kg dosing regimen were only 3.3 after seda-
tion initiation and 4.5 after completion of the procedure. 
The requirement for alternative rescue sedation in 72% of 
patients in the FP 2.0 mg/kg group was one important factor 
playing a role in these lower physician satisfaction scores. In 
contrast, the higher dose of FP 6.5 mg/kg required alternative 
sedation in 12% of patients. This regimen was associated 
with higher physician satisfaction scores of 7.1 after seda-
tion initiation and 7.7 upon colonoscopy completion. The 
authors concluded that FP at a dose of 6.5 mg/kg achieves 
a high level of patient and physician satisfaction, amnesia 
during the procedure in most patients, and a willingness of 
96% of patients to be sedated again with FP. This dose was 
well tolerated, led to clear-headed recovery, with gener-
ally mild to moderate paresthesias being the most common 
observed side effect.
Data on the use of FP for other endoscopic procedures 
may be applicable to its use for colonoscopy. Vincent and 
colleagues randomized 252 patients undergoing ﬂ  exible 
bronchoscopy to either FP 2.0 mg/kg or FP 6.5 mg/kg and 
both groups received pretreatment with 50 μg of fentanyl 
citrate (Vincent et al 2007). The primary endpoint was 
sedation success, deﬁ  ned as 3 consecutive MOAA/S scores 
of 4 after administration of sedation, completion of the 
bronchoscopy without use of any alternative sedatives, 
and without need for mechanical or manual ventilation. 
88.7% of the FP 6.5 mg/kg group achieved sedation suc-
cess compared to only 27.5% in the 2.0 mg/kg group. 
Sedation-related adverse events occurred in 20.1% of 
the standard dose FP and 12.6% of the low dose FP arm. 
Although no deaths occurred during the study, one patient 
with a history of severe hypoxemia, COPD, and recurrent 
pneumonia who was randomized to the FP 6.5 mg/kg 
required bag-valve mask ventilation following sedation. As 
with other trials, the most common adverse reactions were 
mild, self-limited perineal paresthesias (47.6%), pruritus 
(14.7%), and transient hypoxemia (9.9%). Paresthesias 
and pruritus occurred in a similar percentage of patients in 
each treatment arm. Vincent and colleagues concluded that 
FP 6.5 mg/kg is safe and effective in providing titratable 
sedation for ﬂ  exible bronchoscopy in a patient population 
with signiﬁ  cant comorbid illness.
Training
There remains a need for comprehensive sedation training 
programs to ensure the safety and efﬁ  cacy of all agents for 
sedation including non-anesthetist administered propofol and 
FP (Rex 2006). The American Society for Gastrointestinal 
Endoscopy has made clear recommendations regarding 
training requirements to ensure safe administration of deep 
sedation (American Society for Gastrointestinal Endoscopy 
Training Committee 2004). Speciﬁ  c requirements include 
training in advanced cardiac life support, knowledge of the 
pharmacodynamic and pharmacokinetic principles of each 
agent used for endoscopic sedation, and education on the 
indications and contraindications of each agent to be used. 
Of central importance, practitioners should have a clear 
understanding of strategies for airway assessment and man-
agement including measures to support patients undergoing 
episodes of airway obstruction or apnea during sedation 
(Rex 2006). These broad requirements for administration 
of deep sedation will clearly apply to gastroenterologists 
administering FP as a means to increase safety of this unique 
sedative/hypnotic.
Conclusions
At this time, benzodiazepines remain the most widely uti-
lized class of medication for sedation during endoscopic 
procedures. While benzodiazepines are effective, they have 
several speciﬁ  c drawbacks. These include a notable potential 
for drug-drug interactions, signiﬁ  cant metabolic variability 
between patients, lengthy post-procedural recovery periods, Therapeutics and Clinical Risk Management 2008:4(4) 737
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and a propensity for producing deeper levels of sedation than 
intended (Rex 2006; VanNatta and Rex 2006). One recent 
study found that 45% of patients undergoing colonoscopy 
with a combination of a benzodiazepine and opiate for 
sedation experienced transient deep sedation at some time 
throughout the procedure (VanNatta and Rex 2006). In light 
of these notable drawbacks, propofol is often the sedative of 
choice for gastroenterologists. However, gastroenterologist 
use of propofol remains quite limited due to the package 
insert approved by the FDA which speciﬁ  es that use of 
propofol should be limited to individuals “trained in the 
administration of general anesthesia” (AstraZeneca Phar-
maceuticals 2004).
FP may be an attractive agent for gastroenterologists 
interested in realizing the beneﬁ  ts of propofol without the 
requirement of an anesthesia specialist in the endoscopy 
suite. Preliminary studies demonstrate that FP 6.5 mg/kg 
after intravenous bolus dosing of fentanyl citrate 50 μg is 
well tolerated with a slower pharmacodynamic and pharma-
cokinetic proﬁ  le than propofol lipid emulsion. At this dose, 
FP offers an excellent balance of safety and efﬁ  cacy while 
producing high rates of patient and physician satisfaction. 
The clinical use of FP will necessitate full disclosure to 
patients of potential side effects of the agent, which include 
mild to moderate perineal paresthesias and pruritus. Peri-
neal tingling, itching, or burning may occur in up to 85% 
of patients and ultimately may limit patient acceptance of 
this agent for sedation (Pruitt et al 2005). As with all agents 
employed for endoscopic sedation, adequate monitoring of 
a patient’s cardiovascular and respiratory status remains 
essential for safe use of FP.
There are several areas that are ripe for further research 
into the use of FP for sedation during gastroenterologic 
procedures. To date, there is no published literature on 
its use during advanced procedures such as endoscopic 
ultrasound or endoscopic retrograde cholangiopancrea-
tography. These procedures typically require more time to 
complete and FP may have a different safety and efﬁ  cacy 
proﬁ  le in such settings. Additionally, no large scale trials 
exist that directly compare outcomes of propofol emulsion 
with FP for any endoscopic procedure. These data will be 
essential prior to drawing ﬁ  nal conclusions on the relative 
efﬁ  cacy of these agents. While FP does appear to have 
promising applications in sedation during gastroenterologic 
procedures, we must eagerly await ﬁ  nal conclusions from 
further phase III clinical trials before rendering deﬁ  nitive 
conclusions as to where FP sits in the armamentarium of 
endoscopic sedation.
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